STAT Plus: Novo Nordisk offers programs to lower insulin costs as pressure over pricing mounts




In the face of mounting criticism over insulin prices, Novo Nordisk (NVO) is mimicking its rivals by launching two programs that are designed to mitigate rising costs for patients.

The two-pronged effort involves a $99 cash card that can be used by anyone — regardless of whether they have insurance coverage — for a month’s supply and the introduction of authorized generic versions of two different insulin products at half the list price. These will be identical to the Novolog and Novolog Mix brand-name treatments and will be made at the same facility, but will carry modified labeling.

Continue to STAT Plus to read the full story…



Source link

Leave a Reply!

So glad to see you sticking around!

Want to be the first one to receive the new stuff?

Enter your email address below and we'll send you the goodies straight to your inbox.

Thank You For Subscribing!

This means the world to me!

Spamming is not included! Pinky promise.